Translation Control Therapeutics, a novel approach for the discovery of small molecules that selectively control mRNA translation as a new strategy against hard targets and undruggable proteins
$30 million in upfront payments, $14 million in research funding, up to $1.05 billion in milestones and low to mid single-digit tiered royalties on sales of any Lilly products resulting from the collaboration.
Up to $120 million in upfront and preclinical research milestone payments, up to $1.1 billion in clinical and commercial milestones and tiered royalties on sales of any Takeda products resulting from the collaboration. Takeda has a time limited option to expand the collaboration subject to additional payments to Anima of up to $1.2 billion and tiered royalties.
For partnering inquiries, please contact [email protected].
Small molecule drugs targeting novel proteins involved in the regulation of mRNA translation
The Selectivity of Translation Biology
Cells control protein translation using multiple selective mechanisms, offering novel intervention points. Modulation of translation is therefore possible with highly selective drugs.
mRNA translation modulators
A novel target space
Selective translation modulators with novel mechanisms of action elucidated by Anima’s proprietary technologies
Translation Control Therapeutics platform
Our proprietary platform controls mRNA Translation Biology
Anima’s science is using fluorescently labeled tRNA pairs to generate FRET signals, light pulses emitted from the ribosomes to visualize the translation of any protein of interest and identify selective translation modulators
mRNA Translation Modulators Pipeline
Anima wholly owned pipeline programs are in Fibrosis (tissue selective Collagen I translation inhibitors), Oncology (c-Myc translation inhibitors and K-Ras translation inhibitors), Infectious diseases (RSV viral proteins translation inhibitors) and Neuroscience (Tau translation inhibitors and Repeat Associated Diseases, against translation malfunctions in multiple neurological diseases). In addition to our own pipeline, we established strategic collaborations with Pharma in partnered programs including our collaborations with Lilly and Takeda in Neuroscience.
17 Scientific Collaborations
15 Peer Reviewed Publications
Nucleic Acids Res. 2020 ;46(6):e32
Integr Biol (2016); 8 :645-53
Eur J Cell Biol (2018) ; 97 : 168-179.
J Cell Biol. 2016; 23;213(4):451-62.
News & Events
Undruggable Leaders Forum Europe
When: Apr. 13th, 2021 - Apr. 14th, 2021
Anima Biotech has been invited to present a corporate overview at the Undruggable Leaders Forum Europe. Yochi Slonim, Co-founder and Chief Executive Officer of Anima Biotech, and Iris Alroy, Ph.D., Vice President of Research and Development, will present a corporate overview during a session titled, “Novel Approach for the Discovery of Small Molecules that Selectively Control mRNA Translation as a New Strategy Against Undruggable Proteins.”
Anima Biotech Announces Strategic Collaboration with Takeda to Discover and Develop mRNA Translation Modulators for Neurological Diseases
When: Mar. 18th, 2021
Anima Biotech, the leader in the discovery of small molecule drugs that selectively control mRNA translation, today announced that the company has entered into a strategic collaboration with Takeda Pharmaceutical Company Limited (“Takeda”) to discover and develop a new class of medicines for genetically-defined neurological diseases.
Targeting RNA Virtual Summit
When: Mar. 15th, 2021 - Mar. 17th, 2021
Anima Biotech has been invited to present a corporate overview and participate in a panel discussion at the Targeting RNA Virtual Summit. Yochi Slonim, Co-founder and Chief Executive Officer of Anima Biotech, and Iris Alroy, Ph.D., Vice President of Research and Development, will present a corporate overview and Dr. Alroy will serve as an expert on a panel titled, “Approaching mRNA from different angles to target undruggable proteins.